Tag: Mesothelioma News

The U.S. Food and Drug Administration has granted Fast-Track Designation this week to ONCOS-102, an immunotherapy vaccine that targets malignant mesothelioma and other hard-to-treat tumors. This designation is expected to expedite the regulatory approval process. The vaccine’s developer, Targovax, a small biotech company that focuses on oncolytic viruses, sees this as an early endorsement from the FDA. […]

The post FDA Fast-Tracks Mesothelioma Vaccine Development appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

The U.S. Food and Drug Administration has granted Fast-Track Designation this week to ONCOS-102, an immunotherapy vaccine that targets malignant mesothelioma and other hard-to-treat tumors. This designation is expected to expedite the regulatory approval process. The vaccine’s developer, Targovax, a small biotech company that focuses on oncolytic viruses, sees this as an early endorsement from…

The post FDA Fast-Tracks Mesothelioma Vaccine Development appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

More than ever, Dr. Michele Carbone at the University of Hawaii Cancer Center believes early testing for genetic mutations can lead to fewer cases of malignant mesothelioma and a longer survival time for many who do contract the disease. Lives can be saved. Years can be added. “It could change the way we treat these patients,” Carbone told The […]

The post Research Reinforces Gene Mutation Links to Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

More than ever, Dr. Michele Carbone at the University of Hawaii Cancer Center believes early testing for genetic mutations can lead to fewer cases of malignant mesothelioma and a longer survival time for many who do contract the disease. Lives can be saved. Years can be added. “It could change the way we treat these…

The post Research Reinforces Gene Mutation Links to Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

More than two years after implementing a much-celebrated ban of asbestos, Canadians have come to realize the real fight has only just begun. Malignant mesothelioma cancer isn’t going away any time soon. Asbestos exposure may be the only confirmed cause of mesothelioma, but the nationwide ban of the toxic mineral is not predicted to slow the rise in cases […]

The post Mesothelioma Still Prevalent in Canada Following Asbestos Ban appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

More than two years after implementing a much-celebrated ban of asbestos, Canadians have come to realize the real fight has only just begun. Malignant mesothelioma cancer isn’t going away any time soon. Asbestos exposure may be the only confirmed cause of mesothelioma, but the nationwide ban of the toxic mineral is not predicted to slow…

The post Mesothelioma Still Prevalent in Canada Following Asbestos Ban appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

A recent study out of the United Kingdom finds patients with relapsed malignant mesothelioma can be treated effectively with single-agent nivolumab, safely improving overall and progression-free survival. Nivolumab, also known by the brand name Opdivo, is an immunotherapy drug already being used successfully with non-small cell lung cancer. It is the first drug to show a significant survival […]

The post Opdivo Study Offers Hope to Relapsed Mesothelioma Patients appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

A recent study out of the United Kingdom finds patients with relapsed malignant mesothelioma can be treated effectively with single-agent nivolumab, safely improving overall and progression-free survival. Nivolumab, also known by the brand name Opdivo, is an immunotherapy drug already being used successfully with non-small cell lung cancer. It is the first drug to show…

The post Opdivo Study Offers Hope to Relapsed Mesothelioma Patients appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Clinical trials for mesothelioma need more inclusive criteria to better reflect the patients being seen at major cancer treatment centers, according to a recent study conducted in Sydney, Australia. The study demonstrated a significant difference between those carefully selected for clinical trials and real-world patients with pleural mesothelioma. “A broader patient population more resembling real life would be able to access […]

The post Researchers: Mesothelioma Trials Need More Inclusive Criteria appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Clinical trials for mesothelioma need more inclusive criteria to better reflect the patients being seen at major cancer treatment centers, according to a recent study conducted in Sydney, Australia. The study demonstrated a significant difference between those carefully selected for clinical trials and real-world patients with pleural mesothelioma. “A broader patient population more resembling real…

The post Researchers: Mesothelioma Trials Need More Inclusive Criteria appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

The Asbestos Disease Awareness Organization continued its challenge of the U.S. Environmental Protection Agency, filing a petition for review Jan. 26 in the U.S. Court of Appeals for the Ninth Circuit and an intent to sue notice under the Toxic Substances Control Act. ADAO, the leading nonprofit aimed at preventing asbestos exposure and raising awareness…

The post EPA’s Asbestos Risk Evaluation Faces Litigation appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

The Asbestos Disease Awareness Organization continued its challenge of the U.S. Environmental Protection Agency, filing a petition for review Jan. 26 in the U.S. Court of Appeals for the Ninth Circuit and an intent to sue notice under the Toxic Substances Control Act. ADAO, the leading nonprofit aimed at preventing asbestos exposure and raising awareness about mesothelioma, was joined by […]

The post EPA’s Asbestos Risk Evaluation Faces Litigation appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Using accelerated high-dose radiation prior to surgery produced an unprecedented 65.9-month median survival for a cohort of pleural mesothelioma patients who were part of a larger clinical trial at the Princess Margaret Cancer Centre in Toronto. Lancet Oncology recently published results of the study, named SMART, an acronym for Surgery for Mesothelioma After Radiation Therapy….

The post Study: Mesothelioma Survival Rates Rise with SMART Protocol appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Thoracic surgeon Dr. Marcello Migliore is convinced that adding hyperthermic intrathoracic chemotherapy to aggressive surgery can extend survival significantly for patients with pleural mesothelioma cancer. He wants others to know that, too. This seldom-used, controversial procedure, also known as HITHOC, involves circulating a heated, high-concentration chemotherapy solution throughout the chest cavity for 60 minutes immediately…

The post Thoracic Chemotherapy May Advance Mesothelioma Treatment appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Researchers in Europe may have found the key to making immunotherapy drugs such as Opdivo and Keytruda more effective for a larger percentage of patients with malignant pleural mesothelioma. Statins may be the answer. While treatment with those heralded immunotherapy drugs have worked wonders for some, the majority of mesothelioma patients get little or no…

The post Statins May Give Boost to Mesothelioma Immunotherapy Drugs appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.